Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
What is your experience with using oral roflumilast for psoriatic arthritis?
Related Questions
Do you generally attempt to taper and discontinue biologics in a patient with psoriatic arthritis who is in clinical remisson?
Do you utilize serial MRI imaging in patients with axial spondyloarthritis to ensure good disease control or do you rely on symptoms and physical exam to assess treatment response?
Is it safe to use one TNF inhibitor (e.g., infliximab) in a patient who has had a severe allergic reaction to a different TNF inhibitor (e.g., adalimumab)?
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you use biologic DMARDs for active axial spondyloarthritis in transplant patients on long-term anti-rejection therapy?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
